PubMed چکیده/رکورد

Gut microbiota in kidney transplantation: Mechanistic insights and implications for precision immunosuppression.

استودیوی صوتی مقاله

پخش حرفه‌ای فارسی و انگلیسی

در حال بررسی نسخه‌های صوتی ذخیره‌شده…

صوت تولیدشده با هوش مصنوعی است. برای کاربرد علمی یا درمانی، متن و منبع اصلی را بررسی کنید.
خواندن هوشمند فارسی و انگلیسی در حال آماده‌سازی صداهای مرورگر…
تنظیم صدای طبیعی و سرعت

صداهایی که در نامشان «Natural»، «Neural» یا «Online» دیده می‌شود معمولاً طبیعی‌ترند. انتخاب صدا به صداهای نصب‌شده در ویندوز و مرورگر شما بستگی دارد.

چکیده اصلی

Kidney transplantation represents the optimal treatment for eligible patients with end-stage renal disease (ESRD), yet long-term graft survival remains threatened by rejection, infection, and immunosuppressant-related toxicity. Increasing evidence identifies the gut microbiome as an important modulator of these outcomes through the bidirectional gut-kidney axis. After kidney transplantation, microbial dysbiosis is commonly characterized by reduced diversity, enrichment of pathobionts such as Escherichia-Shigella and Enterococcus, and depletion of short-chain fatty acid (SCFA)-producing bacteria, including Faecalibacterium prausnitzii and members of the Lachnospiraceae family. These alterations are driven by the combined effects of pre-existing uremia, surgical and ischemia-reperfusion stress, immunosuppressive therapy, and antimicrobial exposure. Mechanistically, impaired barrier integrity and reduced SCFA production promote systemic inflammation and disrupt the regulatory T-cell (Treg)/T helper 17-cell (Th17) balance, whereas tryptophan metabolites and aryl hydrocarbon receptor signaling further influence alloimmune responses. The microbiota also contributes to variability in immunosuppressant efficacy and toxicity. Bacterial metabolism of tacrolimus and microbiota-mediated regulation of intestinal ABCB1 expression may account for a clinically relevant proportion of tacrolimus pharmacokinetic variability, while bacterial beta-glucuronidase reactivates mycophenolic acid in the intestine and contributes to mycophenolate mofetil-associated gastrointestinal toxicity. Microbiota-derived uremic toxins may additionally reinforce oxidative stress and graft fibrosis. Although fecal microbiota transplantation, precision nutrition, probiotics, and postbiotics show therapeutic potential, current evidence remains largely observational or exploratory. Multicenter randomized controlled trials are therefore required before microbiome-based strategies can be incorporated into routine precision immunosuppression.

متن کامل اصلی

متن در JumpToDate ذخیره نشده است.

برای بررسی دسترسی کتابخانه‌ای یا خرید، رکورد اصلی را باز کنید.

رفتن به منبع اصلی

کلیدواژه‌ها

Fecal microbiota transplantationGut microbiotaImmunoregulationKidney transplantationShort-chain fatty acidsUremic toxins
در همین زیرشاخه

مقاله‌های مرتبط

PubMed2026

ATI-2341 TFA promotes acquisition of epithelial-like immunophenotype in bone marrow mesenchymal stem cells and alleviates intrauterine adhesion in a rat model.

BACKGROUND: Intrauterine adhesion (IUA) is a common complication of endometrial injury. Bone marrow mesenchymal stem cells (BMSCs) have been implicated in endometrial repair, but strategies to enhance their therapeutic efficacy remain to be optimized. The C-X-C chemokine receptor type 4 (CXCR4)/C-X-C motif chemokine ligand 12 (CXCL12) axis plays a pivotal role in BMSC homing. OBJECTIVE: This study aimed to test the hypothesis that ATI-…

PubMed2026

Corrigendum to: Bone marrow mesenchymal stem cells relieve rheumatoid arthritis by blocking JAK/STAT and TLR-4/NF-?B pathways.

The authors have informed the Pakistan Journal of Pharmaceutical Sciences (PJPS) of an error in Figure 5 of the published article. During the editorial revision process, an incorrect version of Figure 5 was inadvertently included in the final published version. The authors have confirmed that the extreme-right panel (panel D) should be removed and that the remaining panels constitute the corrected Figure 5. Accordingly, Figure 5 is cor…

PubMed2026

Better to Be Lucky Than Good: How Clinicians and Patients Frame Medical Outcomes.

Notions of good or bad luck sit uncomfortably in contemporary medical practice defined by efforts to control life through biomedical knowledge and skilled expertise. Yet, talk about luck is common in healthcare to explain medical courses of action. Framing medical results as fortunate or unfortunate bridges the gap between predicted probabilities and variation in individual cases without undermining scientific neutrality. Luck mediates…

PubMed2026

Bone marrow mesenchymal stem cells relieve rheumatoid arthritis by blocking JAK/STAT and TLR-4/NF-κB pathways.

BACKGROUND: Rheumatoid arthritis (RA) is a chronic autoimmune disorder characterized by synovial inflammation and joint destruction. Bone marrow mesenchymal stem cells (BMSCs) have shown therapeutic potential in RA, but the underlying mechanisms remain poorly understood. OBJECTIVES: To investigate the effects of BMSCs on human RA fibroblast-like synovial MH7A cells and complete Freund's adjuvant (CFA)-induced arthritis in rats and to e…